APC Anti-SOCS2 antibody [EPR2588(2)],Abcam,AB319235

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

Host

Rabbit

Reactivity

Human

Application

Target Binding Affinity, Flow Cyt (Intra), ICC/IF, Antibody Labelling

Conjugate

APC

Platform ID

BAB524348865

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Abcam

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Email:

[email protected]

Product Specifications
Scientific Background

Specifications

NameAPC Anti-SOCS2 antibody [EPR2588(2)]
Cat. No.AB319235
HostRabbit
IsotypeIgG
ReactivityHuman
ConjugationAPC
ApplicationTarget Binding Affinity, Flow Cyt (Intra), ICC/IF, Antibody Labelling
ClonalityMonoclonal
Clone NumberEPR2588(2)
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 1% BSA
Storage+4°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Substrate-recognition component of a cullin-5-RING E3 ubiquitin-protein ligase complex (ECS complex, also named CRL5 complex), which mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as EPOR and GHR (PubMed : 11781573, PubMed : 21980433, PubMed : 25505247, PubMed : 31182716, PubMed : 34857742). Specifically recognizes and binds phosphorylated proteins via its SH2 domain, promoting their ubiquitination (PubMed : 21980433, PubMed : 25505247, PubMed : 31182716, PubMed : 34857742, PubMed : 37816714). The ECS(SOCS2) complex acts as a key regulator of growth hormone receptor (GHR) levels by mediating ubiquitination and degradation of GHR, following GHR phosphorylation by JAK2 (PubMed : 21980433, PubMed : 25505247, PubMed : 34857742). The ECS(SOCS2) also catalyzes ubiquitination and degradation of JAK2-phosphorylated EPOR (PubMed : 11781573). See full target information SOCS2

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.